Ischemic stroke prevention

被引:2
作者
Seemant Chaturvedi
Susan Hickenbottom
Steven R. Levine
机构
[1] Wayne State University School of Medicine,
[2] University of Michigan Medical Center,undefined
关键词
Warfarin; Clopidogrel; Dipyridamole; Ticlopidine; Stroke Prevention;
D O I
10.1007/s11940-999-0011-y
中图分类号
学科分类号
摘要
More than 700,000 strokes occur annually in the United States—one every 40 to 50 seconds. Although stroke is one of the nation’s most expensive diseases to treat, costing $41 billion per year, most strokes (perhaps as many as two thirds) are preventable. Twenty percent of the United States population will have 80% of all strokes; this estimate is based on five established, major risk factors for stroke: hypertension, diabetes mellitus, cigarette smoking, hyperlipidemia, and heart disease. Therefore, stroke is not random but is generally predictable. It is an ideal target for effective prevention strategies that are simple and inexpensive. Ischemic stroke prevention has been shown to be effective in several scenarios: primary prevention, prevention after a transient ischemic attack (TIA), and secondary prevention. Dietary, lifestyle, and risk factor modification; use of aspirin, ticlopidine, clopidogrel, and warfarin; and carotid endarterectomy all have a role in stroke prevention in selected persons. Emerging therapies include the use of vitamins, cerebral arterial angioplasty, and stenting. Annual risk assessment, screening, and intervention should be part of a concerted national effort to reduce the incidence of the third leading cause of death and the number one cause of adult disability in the United States.
引用
收藏
页码:113 / 125
页数:12
相关论文
共 90 条
[11]  
Bronner LL(1989)A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group N Engl J Med 321 501-507
[12]  
Kanter DS(1989)The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke Lancet 1 1215-1220
[13]  
Manson JE(1998)A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE) Lancet 348 1329-1339
[14]  
Sacco RL(1982)Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-agregants plaquettaires Rev Neurol (Paris) 138 367-385
[15]  
Elkind M(1985)“AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia Stroke 14 5-14
[16]  
Boden-Albala B(1985)Persantine aspirin trial in cerebral ischemia. Part II: endpoint results Stroke 16 406-415
[17]  
Peto R(1996)European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke J Neurol Sci 143 1-13
[18]  
Gray R(1994)Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1449-1457
[19]  
Collins R(1997)The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials Arch Intern Med 157 1237-1240
[20]  
Hass WK(1994)Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study Lancet 343 687-691